Moleculin Biotech Inc (MBRX)
2.90
+0.07
(+2.47%)
USD |
NASDAQ |
Nov 22, 15:06
Moleculin Biotech Enterprise Value: -0.9096M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -0.9096M |
| November 20, 2024 | -1.390M |
| November 19, 2024 | -1.555M |
| November 18, 2024 | -1.840M |
| November 15, 2024 | -1.270M |
| November 14, 2024 | -0.1291M |
| November 13, 2024 | -1.870M |
| November 12, 2024 | -1.48M |
| November 11, 2024 | -1.870M |
| November 08, 2024 | -1.750M |
| November 07, 2024 | -2.381M |
| November 06, 2024 | -2.501M |
| November 05, 2024 | -2.080M |
| November 04, 2024 | -2.050M |
| November 01, 2024 | -2.050M |
| October 31, 2024 | -1.600M |
| October 30, 2024 | -1.780M |
| October 29, 2024 | -1.54M |
| October 28, 2024 | -1.54M |
| October 25, 2024 | -1.675M |
| October 24, 2024 | -1.780M |
| October 23, 2024 | -1.750M |
| October 22, 2024 | -1.750M |
| October 21, 2024 | -1.390M |
| October 18, 2024 | -1.645M |
| Date | Value |
|---|---|
| October 17, 2024 | -2.320M |
| October 16, 2024 | -2.140M |
| October 15, 2024 | -2.411M |
| October 14, 2024 | -2.290M |
| October 11, 2024 | -2.080M |
| October 10, 2024 | -2.110M |
| October 09, 2024 | -1.750M |
| October 08, 2024 | -1.900M |
| October 07, 2024 | -1.870M |
| October 04, 2024 | -2.320M |
| October 03, 2024 | -2.020M |
| October 02, 2024 | -1.840M |
| October 01, 2024 | -1.030M |
| September 30, 2024 | -0.8796M |
| September 27, 2024 | -3.023M |
| September 26, 2024 | -3.904M |
| September 25, 2024 | -3.990M |
| September 24, 2024 | -3.193M |
| September 23, 2024 | -3.136M |
| September 20, 2024 | -4.104M |
| September 19, 2024 | -3.848M |
| September 18, 2024 | -3.819M |
| September 17, 2024 | -4.189M |
| September 16, 2024 | -3.990M |
| September 13, 2024 | -3.933M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-35.75M
Minimum
Mar 14 2022
141.14M
Maximum
Feb 10 2021
6.310M
Average
-4.712M
Median
Enterprise Value Benchmarks
| Agilent Technologies Inc | 39.10B |
| Seelos Therapeutics Inc | 10.03M |
| Cara Therapeutics Inc | -25.03M |
| Citius Pharmaceuticals Inc | 12.53M |
| NovaBay Pharmaceuticals Inc | 2.798M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.59M |
| Total Expenses (Quarterly) | 7.135M |
| EPS Diluted (Quarterly) | -2.85 |
| Earnings Yield | -406.0% |